CAR-T oncology market expands as ALL and lymphoma therapies target long-term growth
Resolved · regulation · Occurred · Assessed · 2 sources
This assessment is dated 2026-09-16. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Earlier-line indication approvals and allogeneic cell therapy adoption expand commercial revenue runways for GILD and NVS CAR-T oncology portfolios.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factThe CAR-T cell therapy market for Non-Hodgkin Lymphoma is projected to expand at a 7% CAGR from 2026 through 2036, rising from a 2025 baseline of $3.20 billion across seven major markets. |
| What else was confirmed? | Reported factThe acute lymphoblastic leukemia (ALL) CAR-T market is projected to grow at a 6.8% CAGR from 2026 to 2036 from $300 million in 2025. |
| Does the valuation support acting? | Interpretation2 stored valuation assumptions for GILD; the latest is dated 2026-09-02. |
| What would change the assessment? | UnknownGilead oncology cell therapy sales figures — Track Yescarta and Tecartus commercial revenue growth in upcoming Q3 disclosures. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · The CAR-T cell therapy market for Non-Hodgkin Lymphoma is projected to expand at a 7% CAGR from 2026 through 2036, rising from a 2025 baseline of $3.20 billion across seven major markets.
- · The acute lymphoblastic leukemia (ALL) CAR-T market is projected to grow at a 6.8% CAGR from 2026 to 2036 from $300 million in 2025.
- · Key commercial therapies driving adoption include Kymriah (Novartis), Tecartus (Gilead Sciences), and Aucatzyl (Autolus), with clinical advancement focusing on earlier-line use and allogeneic cell platforms.
Public research record
Research framework · page evidenceCompleted event assessment
oncology cell therapy volume growth via Tecartus label expansion
| Type | Claim | Scope |
|---|---|---|
| Assumption | The CAR-T cell therapy market for Non-Hodgkin Lymphoma is projected to expand at a 7% CAGR from 2026 through 2036, rising from a 2025 baseline of $3.20 billion across seven major markets. | 2026-09-16 |
| Assumption | The acute lymphoblastic leukemia (ALL) CAR-T market is projected to grow at a 6.8% CAGR from 2026 to 2036 from $300 million in 2025. | 2026-09-16 |
| Interpretation | oncology cell therapy volume growth via Tecartus label expansion | GILD |
Countercase, invalidators, and sources
Regulatory bodies approve earlier-line CAR-T indications, accelerating clinical adoption and exceeding the 7% projected CAGR.
- · Gilead oncology cell therapy sales figures — Track Yescarta and Tecartus commercial revenue growth in upcoming Q3 disclosures.
- · Autolus Aucatzyl commercial rollout data — Evaluate treatment center onboarding and patient access metrics in ALL.
- CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036 · 2026-09-16
- CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036 · 2026-09-16
What remains unresolved
- Base path
- Steady clinical uptake in major hospital networks delivers high single-digit revenue growth across commercial cell therapy franchises.
- Adverse path
- Manufacturing turnaround constraints and safety monitoring requirements limit patient access, capping commercial adoption rates.
- Supportive path
- Regulatory bodies approve earlier-line CAR-T indications, accelerating clinical adoption and exceeding the 7% projected CAGR.
- · Gilead oncology cell therapy sales figures — Track Yescarta and Tecartus commercial revenue growth in upcoming Q3 disclosures.next month
- · Autolus Aucatzyl commercial rollout data — Evaluate treatment center onboarding and patient access metrics in ALL.next month
Gilead oncology cell therapy sales figures; Autolus Aucatzyl commercial rollout data
Evidence
- CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 20362026-09-16
“The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms.”
Supports: NHL CAR-T market projected to grow at 7% CAGR through 2036 from $3.20B baseline across seven major markets.
- CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 20362026-09-16
“The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL.”
Supports: ALL CAR-T market projected to grow at 6.8% CAGR from $300M in 2025 driven by Kymriah, Tecartus, and Aucatzyl.